This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Blood centers are neutral partners, as they do not compete with hospitals for patients. Instead, they complement hospitals by providing a focused array of high-quality, specialized, patient-centric services, allowing hospitals to maintain primary relationships with patients and their families. The post Blood Centers Complement Hospitals to Drive Cell and Gene Therapy Access appeared first on MedCity News.
"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B. The post Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity appeared first on MedCity News.
New clinical research from the UK has revealed the significant potential of a gene therapy to treat young children with AIPL1-related retinal dystrophy. Findings of the first-in-human study, published in The Lancet , reported that the four children with the rare genetic deficiency benefited substantially, as they gained strong improvements in their eyesight.
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
The conversations in Nashville reinforced the idea that while innovation remains essential, vendors must navigate the fine balance between bold ideas and real-world implementation, demonstrating not just promise but tangible outcomes. The post ViVE 2025: The Crossroads of Digital Health Innovation and Realities appeared first on MedCity News.
Prostate cancer (PC) remains a significant men's health concern, demanding innovative treatment strategies and precise commercialization approaches. While claims data offers a cost-effective starting point for understanding patient journeys and treatment patterns, it often lacks the granular detail needed to optimize the commercial success of new therapies.
Prostate cancer (PC) remains a significant men's health concern, demanding innovative treatment strategies and precise commercialization approaches. While claims data offers a cost-effective starting point for understanding patient journeys and treatment patterns, it often lacks the granular detail needed to optimize the commercial success of new therapies.
Future Family launched a nationwide IVF insurance product on Wednesday. If families don’t achieve a live birth after two cycles of IVF, they can get their money back. The post Future Family Guarantees ‘Baby or Your Money Back’ with New Nationwide IVF Insurance appeared first on MedCity News.
San Diego, California, February 20 2025 DistillerSR Inc., the market leader in literature review automation software and creator of DistillerSR , today announced an agreement to expand its collaboration with CCC so that DistillerSR users can submit orders for scholarly journal articles directly from CCCs RightFind Enterprise software solution. Available today, this integration saves time for users by eliminating the need for systematic review teams to log into multiple systems and websites to o
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
James D. Chambers, PhD, MPharm, MSc, professor of medicine at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, dives into why biosimilars contribute to a reduction in cost and increase in patient access, while highlighting challenges to adoption.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood sugar.
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
Pistoia Alliance President Becky Upton, Ph.D. explains pharma and clinical research organizations must collaborate to address copyright and data-sharing challenges with or AI — or risk stalling innovation.
In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on other concepts that are powering the companys 2025 Supply Chain Trends Report, and how they could possibly change in 2026.
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
233 
Let's personalize your content